Advisors from the U.S. Food and Drug Administration (FDA) are set to discuss this week whether seven widely-used peptides should be allowed to be compounded by licensed pharmacies. However, industry experts believe that regardless of the regulators’ decision, consumer interest in these substances will likely remain high.
This review comes as peptides transition from specialized anti-aging clinics into the expanding wellness sector, driven by social media influencers, biohacking communities, and support from Health Secretary Robert F. Kennedy Jr.
Peptides, which are short sequences of amino acids, are claimed by supporters to enhance recovery, boost performance, and help with various health issues. Among those under evaluation are three popular options: BPC-157, TB-500, and Semax, which have gained a following among fitness enthusiasts and biohackers.
Last month, FDA staff reviewers noted a lack of substantial evidence supporting the safety and efficacy of these peptides for their intended purposes, highlighting the absence of sufficient human clinical trials, despite Kennedy’s public backing.
Kennedy, who has reported positive effects from using peptides, contends that existing restrictions have led consumers to seek these compounds from unregulated grey markets.
The FDA’s Pharmacy Compounding Advisory Committee is scheduled to convene on Wednesday and Thursday to evaluate whether to include these seven peptides on the agency’s 503A Bulks List, which would enable state-licensed compounding pharmacies to create these substances for patients with prescriptions.
Any recommendation made by the committee will be advisory and not obligatory for the agency. Several members of the voting panel are affiliated with businesses or clinics involved in peptide therapies, raising concerns about potential conflicts of interest.
Increasing Interest
Despite the limited data, the demand for peptides has been on the rise. Online communities on platforms like Reddit have become popular spaces for peptide users to share personal anecdotes, discuss the latest studies, and compare suppliers and quality assurance services.
This growing interest has contributed to a grey market where consumers seek access to research-grade injections, including experimental weight-loss treatments such as retatrutide.
“Regardless of our opinions on every current application, peptides have entered the mainstream, and this level of public fascination is unlikely to fade,” stated Carrie Carda, national medical director at 10X Health.
The company currently provides peptide therapies and has stated it will adhere to any regulatory changes to ensure a smooth transition for patient care.
On Wednesday, over 100 individuals plan to gather outside the FDA campus in Maryland, urging the agency to broaden access to peptides.
Balancing Regulation and Restriction
The FDA’s actions in 2023 targeting compounded peptides limited access through licensed pharmacies but did not significantly reduce demand.
Some experts believe that peptides necessitate distinct testing protocols compared to pharmaceutical drugs.
“The wellness industry is predominantly consumer-driven, rather than being dictated by clinicians or pharmaceutical corporations,” remarked Jeff Cohen, a founder of the American Peptide Association.
He noted that many peptides are naturally occurring substances that do not possess the patent protections necessary to justify costly clinical development processes.
In documents prepared for the upcoming meeting, the FDA mentioned that many peptides lack sufficient human safety and efficacy data. The agency raised concerns regarding immunogenicity, indicating limited information on the quality, stability, and consistency of the compounds.
A regulated system where peptides are traceable, independently tested, and prescribed within a medical framework is deemed the safest approach. Patients should be able to verify the origin, manufacturer, and quality of these substances, according to Carda from 10X Health.
In a letter to the committee, the Alliance for Pharmacy Compounding urged the FDA to tackle safety issues via targeted safeguards rather than implementing outright restrictions.
The organization argued that allowing state-licensed pharmacies to compound peptides when there is a genuine patient need would enhance oversight through prescription requirements, quality standards, inspections, and reporting of adverse events.
“The 503A pathway represents the initial step towards accountability, and that is ultimately what we are aiming for. This would enable us to provide patients with more realistic expectations regarding the use of these substances,” stated Michael Hall, founder of Hall Longevity Clinic in Miami Beach, who prescribes peptides to his patients.